Organic Active Ingredients TRIZ Cases

Oral D-Ribose raises ATP levels in neurons to treat restless legs syndrome without the adverse side effects of dopaminergic drugs.

Covalent warhead moiety bonds FGFR-4 cysteine residue, resolving off-target toxicity from non-selective isoform inhibition.

Granular activated carbon impregnated with zero-valent iron chemically reduces energetic compounds into non-toxic by-products.

1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine combines serotonin reuptake inhibition with 5-HT1A partial agonism.

Covalent bonding of heteroaryl compounds to FGFR4 cysteine residues extends inhibition duration beyond pharmacokinetic half-life.

Arylnitro linker uses cathepsin B cleavage to minimize off-target toxicity in antibody-drug conjugates.

Enzymatic conversion of arctiin to arctigenin via beta-glucosidase overcomes poor water solubility and low content for stable anticancer efficacy.

Intranasal tetracaine with oxymetazoline anesthetizes upper teeth without needles, eliminating patient anxiety and bloodborne pathogen risks.

Non-ionic HyPPo polymers form stable coacervates across wide pH ranges, resolving the trade-off between adhesive strength and environmental stability.

Pyridinyl substituted oxoisoindoline compounds inhibit Helios protein via E3 ubiquitin ligase complexes to modulate regulatory T cell function.

Ginsenoside F2 suppresses SREBP1c and FAS gene expressions, reducing inflammatory cytokines in Kupffer cells to treat non-alcoholic liver disease.

Thienopyrimidine derivatives inhibit acetyl-CoA carboxylase with high liver specificity, reducing systemic adverse effects while treating metabolic disorders.

Liquid thermosensitive hydrogel transitions to gel at oral temperature, extending residence time against saliva dilution.

A self-assembling drug delivery system uses electrostatic interactions to bind polypeptides and nucleic acids for targeted molecular transport.

Fluorine-treated support layers stabilize oxybutynin patches, preventing adhesion loss and medication release drift during storage.

Modified algae cellulose maintains amorphous drug states to boost bioavailability and reduce side effects from high doses.

Amide-bond intermediate allows one-step deprotection and hydrolysis, avoiding explosive reagents and severe conditions for industrial mass production.

High molecular weight insoluble elastin reduces foreign body reactions and calcification while maintaining long-term persistence in injected tissues.

Analytical testing controls cannabinoid admixing to resolve inconsistent THC concentration in coffee drinks.

A repair-modulating enzyme molecule directs DNA repair pathways to control nucleic acid alterations at target positions.

A streamlined synthetic route for compound of formula I uses palladium-catalyzed cross-coupling and direct amide coupling to assemble the antiretroviral structure.

Cannabinoid-based oral compositions replace triclosan to inhibit bacterial growth while avoiding antibiotic resistance and hormone imbalance risks.

Substituted pyrazole compounds modulate RORγt to selectively inhibit the Th17 pathway, reducing side effects from non-selective immunosuppression.

A dephosphorylated psychoactive alkaloid extract combined with a mucoadhesive polymer for rapid oral mucosal absorption.

Phthalazinone core derivatives with optimized substituents expand treatment options for chemotherapy toxicities.

Nanocapsoid formulations encapsulate finasteride and minoxidil within biodegradable polymers, overcoming poor follicle retention in standard topical treatments.

An inclusion complex of meloxicam with sulfobutyl ether beta-cyclodextrin resolves poor aqueous solubility to achieve rapid onset of pain relief.

VR23 targets the beta2 subunit to lower myeloperoxidase, bypassing NSAID gastrointestinal risks.

Combines tramadol with its active metabolite O-desmethyltramadol in fixed ratios to maintain optimal plasma levels.

Fused cyclic urea derivatives resolve toxicity and stability trade-offs in CRHR2 antagonism via optimized molecular structures.

MTMR2-S polypeptide rescues muscle weight and force in X-linked centronuclear myopathy by normalizing phosphoinositide levels.

Optimized tPA formulation with sucrose and tranexamic acid maintains stability at room temperature without refrigeration.

Specific excipient ratios ensure homogeneity in low dose pramipexole tablets, resolving manufacturing precision challenges.

Replacing iodinated contrast agents with polysorbates and gluconolactone improves paclitaxel adhesion while preventing nephrogenic systemic fibrosis.

Novel GOAT inhibitors block ghrelin activation, reducing weight gain and improving insulin sensitivity despite treatment complexity.

Conjugating opioid agonists with water-soluble PEG chains modifies molecular size and hydrophilicity to alter pharmacokinetic profiles.

Dipping elastomeric cores in solvent-based solutions creates uniform 5-100 μm membranes, solving adhesion failures in thin film manufacturing.

Phenformin and berberine inhibit melanin decomposition in keratinocytes to increase pigment accumulation.

Measuring blood phosphoethanolamine levels predicts serotonin-noradrenaline reuptake inhibitor effectiveness for depression treatment.

A porous pullulan-collagen scaffold releases a focal adhesion kinase inhibitor to treat large area wounds where mechanical strain off-loading is not applicable.

Formula 1 derivatives overcome drug-resistant neuropathic pain by targeting specific receptor subtypes with enhanced therapeutic efficacy.

Antibodies target angiopoietin-2 specifically without binding angiopoietin-1, preserving vascular protection while inhibiting disease-related angiogenesis.

Engineered g-NK cells express a chimeric antigen receptor and interleukin-15 to drive antibody-dependent cellular cytotoxicity.

Hedgehog pathway inhibitors replace invasive aortic valve replacement surgery by reducing fibrosis and improving cardiac function.

Replacing the platinum center with organic rings reduces toxicity while maintaining efficacy against cervical, breast, and lung cancer cells.

Segmented nanoparticles shield insulin from gastrointestinal enzymes, enabling stable transport across the intestinal mucosa.

Dual CXCR1/CXCR2 receptor inhibitors target inflammatory pathways to treat interstitial cystitis and overactive bladder conditions.